Transgene Biotek Ltd — Board Meeting, 07-08-2025: Board Meeting

Plot 69 &70 , IDA Bollaram, Sangareddy District – 502 325, Telangana, India

Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com

Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065

Date:07-08- 2025

To

The General Manager

Department of Corporate Services,

BSE Ltd.,PhirozeJeejeebhoy Towers,

Dalal Street, Mumbai-400001

Scrip Code: 526139

Respected Sir / Madam,

SubOutcome of the Board Meeting.

This has reference to our letter dated 30

th July 2025.

At a meeting of the Board of Directors of the company held on 07th August 2025 the

followingdecisions have been taken:

1) The Board considered and approved the Unaudited Financial Results (Standalone &

Consolidated) of the Company for the quarter ended 30th June 2025.

2) The Board considered and approved the Limited Review Report (Standalone &

Consolidated) of the Company for the quarter ended 30th June 2025.

3) The Board considered and approved the extension of the date of Annual General

Meeting (AGM) of the Company for the financial year 2024-25.

4) The Board considered and approved the appointment of M/s.Manisha Dubey &

Associates, as Internal Auditors of the Company for the financial year 2025-26.

5) The Board considered and approved the appointment of M/s. Geeta Serwani &

Associates, Practicing Company Secretaries as Secretarial Auditor of the Company

for the term of 5 years effective from 01st April 2025 till 31st March 2030 which is

subject to regularization by shareholders at AGM; (Attached as Annexure A)

The meeting commenced at 11.00 A.M and concluded at 11.45A.M.

Thanking you

Yours Sincerely

For TRANSGENE BIOTEK LIMITED

DR. K. KOTESWARA RAO

CHAIRMAN & MANAGING DIRECTOR

Encls: as above

----------------Page (0) Break----------------

Plot 69 &70 , IDA Bollaram, Sangareddy District – 502 325, Telangana, India

Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com

Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065

Disclosure pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master

Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr.No Particulars

Secretarial Auditor

Internal Auditors

1 Name of Auditors

Ms. GeetaSerwani, Sole

Proprietor of M/s.

GeetaSerwani& Associates,

Practicing Company

Secretaries

Ms. Manisha Dubey, Sole

Proprietor of M/s. Manisha

Dubey & Associates,Internal

Auditors

2 Reason for change: Appointment Appointment of M/s.

GeetaSerwani& Associates, a

Peer Reviewed Firm of

Company Secretaries in

Practice, having Membership

No.F8991, as Secretarial

Auditor of the Company.

Appointment of M/s.Manisha

Dubey& Associates, a Peer

Reviewed Firm of Chartered

Accountant in Practice, having

Membership No.212664, as

Internal Auditor of the

Company.

3 Date of appointment and term of

appointment

The Board at its meeting held

on August 07, 2025, approved

the appointment of M/s.

GeetaSerwani& Associates,

Practicing Company

Secretaries, as Secretarial

Auditors of the Company, for

an audit period of five

consecutive years

commencing from financial

year 2025-26 upto financial

year 2029-30, subject to

approval of the shareholders

at the ensuing Annual General

Meeting.

The Board at its meeting held

on August 07, 2025, approved

the appointment of M/s.

Manisha Dubey & Associates,

Chartered Accountant, as

Internal Auditors of the

Company for the financial

year 2025-26.

4 Brief profile (in case of appointment) Geeta Serwani &Associates,

Sole Proprietorship firm of

Company Secretary. Ms.Geeta

Serwani has more than 14

years

Renowned for its commitment

to quality and providing

precision. professional services

in corporate law, SEBI

regulations, FEMA

compliance, NCLT practices

and allied fields, delivering

strategic solutions to ensure

regulatory adherence and

Ms. Manisha Dubey, Sole

Proprietor firm of Chartered

Accountant.Ms. Manisha

Dubey hasmore than 23 years

“M/s Manisha Dubey &

Associates”, is a Chartered

Accountants firm having

extensive experience in

internal audit and Internal

Financial Controls reviews.

----------------Page (1) Break----------------

Plot 69 &70 , IDA Bollaram, Sangareddy District – 502 325, Telangana, India

Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com

Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065

operational efficiency. The

firm provides its services to

various prominent companies

and their expertise has earned

the trust of industry leaders

across sectors like

banking,manufacturing,

pharmaceuticals, and public

utilities. The firm is peer-

reviewed in terms of the peer

review guidelines issued by the

Institute of Company

Secretaries of India (‘ICSI’)

bearing Peer Review

Certification No. 1893/2022

and unique code S2010GJ125

-900 issued by ICSI

5 Disclosure of relationships between

directors (in case of appointment)

Not applicable Not applicable

----------------Page (2) Break----------------

M/S VASAVI & CO

Chartered Accountants

#8-3-903/4/4, F No 201, Krishna Enclave, Road No 05, Nagarjuna Nagar, Srinagar Colony, Hyderabad – 500073, TG.

Contact No: +91 9652251341, Email: vasavinco@gmai.com

Limited Review report

To

The Board of Directors,

M/s TRANSGENE BIOTEK LIMITED

Hyderabad

We have reviewed the accompanying statement of unaudited standalone financial results of M/s

TRANSGENE BIOTEK LIMITED for the Quarter ended 30th June 2025. This statement is the

responsibility of the Company’s Management and has been approved by the Board of Directors. Our

responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review

Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent

Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard

requires that we plan and perform the review to obtain moderate assurance as to whether the

financial statements are free of material misstatement. A review is limited primarily to inquiries of

company personnel and an analytical procedure applied to financial data and thus provides less

assurance than an audit. We have not performed an audit and accordingly, we do not express an

audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to

believe that the accompanying statement of unaudited financial results prepared in accordance

with applicable accounting standards and other recognized accounting practices and policies has

not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to

be disclosed, or that it contains any material misstatement.

For VASAVI & CO,

Chartered Accountants

FRN 020965S

(CA VASAVI GOLLAPUDI)

Proprietor

MRN 249259

UDIN for this document is: 25249259BMOPZE4252

Place: Hyderabad

Date: 07/08/2025

----------------Page (3) Break----------------

M/S VASAVI & CO

Chartered Accountants

#8-3-903/4/4, F No 201, Krishna Enclave, Road No 05, Nagarjuna Nagar, Srinagar Colony, Hyderabad – 500073, TG.

Contact No: +91 9652251341, Email: vasavinco@gmai.com

Independent Auditor’s Review Report On consolidated unaudited quarterly and year to date

financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,

M/s Transgene Biotek Limited

Hyderabad

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial

Results of M/s Transgene Biotek Ltd (“the Parent”) and its subsidiaries (the Parent and its

subsidiaries together referred to as “the Group”), and its share of the net profit/(loss) after

tax and total comprehensive income / loss of its associates for the quarter ended

30/06/2025 being submitted by the Parent pursuant to the requirement of Regulation 33 of

the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Attention is drawn to the fact that the consolidated figures for the corresponding quarter

ended 30/06/2025 as reported in these financial results have been approved by the

Parent’s Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent’s Management and approved by the

Parent’s Board of Directors, has been prepared in accordance with the recognition and

measurement principles laid down in Indian Accounting Standard 34 “Interim Financial

Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and

other accounting principles generally accepted in India. Our responsibility is to express a

conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review

Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the

Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of

India. A review of interim financial information consists of making inquiries, primarily of

persons responsible for financial and accounting matters, and applying analytical and other

review procedures. A review is substantially less in scope than an audit conducted in

accordance with Standards on Auditing and consequently does not enable us to obtain

assurance that we would become aware of all significant matters that might be identified in

an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under

Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015, as amended, to the extent applicable.

----------------Page (4) Break----------------

M/S VASAVI & CO

Chartered Accountants

#8-3-903/4/4, F No 201, Krishna Enclave, Road No 05, Nagarjuna Nagar, Srinagar Colony, Hyderabad – 500073, TG.

Contact No: +91 9652251341, Email: vasavinco@gmai.com

5. The Statement includes the results of the following entities:

1. Transgene Biotek HK Ltd - Subsidiary

6. Based on our review conducted and procedures performed as stated in paragraph 3 above

and based on the consideration of the review reports of the other auditors referred to in

paragraph below, nothing has come to our attention that causes us to believe that the

accompanying Statement, prepared in accordance with the recognition and measurement

principles laid down in the aforesaid Indian Accounting Standard and other accounting

principles generally accepted in India, has not disclosed the information required to be

disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015, as amended, including the manner in which it is to be

disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of subsidiary included in the Statement,

whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax

of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June

2025, as considered in the consolidated unaudited financial results.

For VASAVI & CO,

Chartered Accountants

FRN 020965S

(CA VASAVI GOLLAPUDI)

Proprietor

MRN 249259

UDIN for this document is: 25249259BMOPZE4252

Place: Hyderabad

Date: 07/08/2025

----------------Page (5) Break----------------

(In Lakhs)

Year to date

figures for

current period

ended

Year to date

figures

Previous year

ended

Year Ended

30-06-2025

(Unaudited)

31-03-2025

(Unudited)

30-06-2024

(Unudited)

30.06.2025

(Unaudited)

30.06.2024

(Unaudited)

31.03.2025

(Audited)

1 Revenue from operations 4.95 7.65 4.92 4.95 4.92 26.07

2 Other income (net) 0.00 4.38 65.19 0.00 65.19 78.353Total income (1 + 2) 4.95 12.03 70.12 4.95 70.12 104.42

4EXPENSES

Cost of materials consumed 0.00 0.00 0.00 0.00 0.00 0.00

Changes in inventories of finished goods, work-

in-progress and Stock-in-trade0.00 0.00 0.00 0.00 0.00 0.00

Employee benefits expense 4.72 6.34 8.09 4.72 8.09 30.78Finance costs

24.5519.121.7324.551.7324.30

Depreciation and amortisation expense4.982.352.324.982.329.32

Other expenses14.0755.5338.0314.0738.03107.62

Total expenses48.32 83.34 50.18 48.32 50.18 172.03

5

Profit before exceptional items, share of

profit from associate & joint venture and tax (3 - 4)-43.37 -71.31 19.94 -43.37 19.94 -67.61

6Exceptional item (net) 0.00 0.00 0.00 0.00 0.00 0.00

7Profit before tax (5 - 6) -43.37 -71.31 19.94 -43.37 19.94 -67.61

8Tax expense

Tax adjustments for earlier years 0.00 0.00 0.00 0.00 0.00 0.00Current tax0.00 0.00 0.00 0.00 0.00 0.00

Deferred tax0.00 0.00 0.00 0.00 0.00 0.00

Total tax expense0.00 0.00 0.00 0.00 0.00 0.00

9Profit for the year (7 - 8) -43.37 -71.31 19.94 -43.37 19.94 -67.61

10Other comprehensive incomeA Items that will not be reclassified subsequently to profit or loss

(a) Remeasurements cost of post employment

benefits0.00 0.00 0.00 0.00 0.00 0.00

Total other comprehensive income0.000.00 0.00 0.00 0.00 0.00

11Total comprehensive income for the year (9 + 10)-43.37 -71.31 19.94 -43.37 19.94 -67.61

12Earnings per equity share

(Equity shares, par value of Rs. 10 each) 757.70 757.70 757.70 757.70 757.70 757.70

Basic (Rs.)(0.06) (0.09) 0.03 (0.06) 0.03 (0.09)

Diluted (Rs.)(0.06) (0.09) 0.03 (0.06) 0.03 (0.09)

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

Sr.

No.Particulars

Quarter Ended

----------------Page (6) Break----------------

Notes:

12345

For TRANSGENE BIOTEK LIMITEDDr.K.Koteswara RaoManaging DirectorDate: 07/08/2025Place:Hyderabad

As a consequence for not getting any relief from SAT as yet on the petition filed against the Adjudication order passed by SEBI, it has been extremely difficult to manage functioning of the company. However, we managed to clear the principle sum owing to BIRACNext date for SAT hearing is scheduled for 08th September 2025

The proceedings have started on 30th July 2025 at the Appellate Tribunal, New Delhi challenging the Adjudication Order passed by the Enforcement

Directorate, Chennai.The auditors have carried out a limited review of the financial results for the quarter ended 30th June 2025 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 07th August 2025.

No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0

----------------Page (7) Break----------------

TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements Other expenses(In Lakhs)

Particulars

For the Period ended

June 2025

Advertisement0.13

BSE Listing & Annual Custody fee 4.86Bank charges0.00

BSNL Fiber net0.04

Business promotional exp0.98

Contract Labour0.09

Conveyance Expenses0.32

Directors sitting fee0.15

FILM Fee- NSDl0.05

Legal and Professional Charges 4.58Miscllaneous Expenses0.01

Muncipal tax2.18

Office Expenses0.05

Rates, taxes and duties0.09

Repairs and maintenance0.01

Telephone Expenses0.03

Travelling Expenses0.00

Website and Software0.45

Professional charges0.06

Total

14.07

For TRANSGENE BIOTEK LIMITEDDr.K.Koteswara RaoManaging DirectorDate: 07/08/2025Place:Hyderabad

----------------Page (8) Break----------------

(In Lakhs)

Year to date

figures for

current period

ended

Year to date

figures

Previous year

ended

Year Ended

30-06-2025

(Unaudited)

31-03-2025

(Unudited)

30-06-2024

(Unudited)

30.06.2025

(Unaudited)

30.06.2024

(Unaudited)

31.03.2025

(Audited)

1 Revenue from operations 4.95 7.65 4.92 4.95 4.92 26.07

2 Other income (net) 0.00 4.38 65.19 0.00 65.19 78.353Total income (1 + 2) 4.95 12.03 70.12 4.95 70.12 104.42

4EXPENSES

Cost of materials consumed 0.00 0.00 0.00 0.00 0.00 0.00

Changes in inventories of finished goods, work-

in-progress and Stock-in-trade0.00 0.00 0.00 0.00 0.00 0.00

Employee benefits expense 4.72 6.34 8.09 4.72 8.09 30.78Finance costs

24.5519.121.7324.551.7324.30

Depreciation and amortisation expense4.982.352.324.982.329.32

Other expenses14.0755.5338.0314.0738.03107.62

Total expenses48.32 83.34 50.18 48.32 50.18 172.03

5

Profit before exceptional items, share of

profit from associate & joint venture and tax (3 - 4)-43.37 -71.31 19.94 -43.37 19.94 -67.61

6Exceptional item (net) 0.00 0.00 0.00 0.00 0.00 0.00

7Profit before tax (5 - 6) -43.37 -71.31 19.94 -43.37 19.94 -67.61

8Tax expense

Tax adjustments for earlier years 0.00 0.00 0.00 0.00 0.00 0.00Current tax0.00 0.00 0.00 0.00 0.00 0.00

Deferred tax0.00 0.00 0.00 0.00 0.00 0.00

Total tax expense0.00 0.00 0.00 0.00 0.00 0.00

9Profit for the year (7 - 8) -43.37 -71.31 19.94 -43.37 19.94 -67.61

10Other comprehensive incomeA Items that will not be reclassified subsequently to profit or loss

(a) Remeasurements cost of post employment

benefits0.00 0.00 0.00 0.00 0.00 0.00

Total other comprehensive income0.000.00 0.00 0.00 0.00 0.00

11Total comprehensive income for the year (9 + 10)-43.37 -71.31 19.94 -43.37 19.94 -67.61

12Earnings per equity share

(Equity shares, par value of Rs. 10 each) 757.70 757.70 757.70 757.70 757.70 757.70

Basic (Rs.)(0.06) (0.09) 0.03 (0.06) 0.03 (0.09)

Diluted (Rs.)(0.06) (0.09) 0.03 (0.06) 0.03 (0.09)

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

Sr.

No.Particulars

Quarter Ended

----------------Page (9) Break----------------

Notes:

12345

For TRANSGENE BIOTEK LIMITEDDr.K.Koteswara RaoManaging DirectorDate: 07/08/2025Place:Hyderabad

As a consequence for not getting any relief from SAT as yet on the petition filed against the Adjudication order passed by SEBI, it has been extremely difficult to manage functioning of the company. However, we managed to clear the principle sum owing to BIRACNext date for SAT hearing is scheduled for 08th September 2025

The proceedings have started on 30th July 2025 at the Appellate Tribunal, New Delhi challenging the Adjudication Order passed by the Enforcement

Directorate, Chennai.

The auditors have carried out a limited review of the financial results for the quarter ended 30th June 2025 and following the approval by the audit

committee, it has been passed by the Board of Directors at the meeting held on 07th August 2025.

No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0

----------------Page (10) Break----------------

TRANSGENE BIOTEK LIMITED

Notes forming part of the Consolidated financial statements Other expenses(In Lakhs)

Particulars

For the Period ended

June 2025

Advertisement0.13

BSE Listing & Annual Custody fee 4.86Bank charges0.00

BSNL Fiber net0.04

Business promotional exp0.98

Contract Labour0.09

Conveyance Expenses0.32

Directors sitting fee0.15

FILM Fee- NSDl0.05

Legal and Professional Charges 4.58Miscllaneous Expenses0.01

Muncipal tax2.18

Office Expenses0.05

Rates, taxes and duties0.09

Repairs and maintenance0.01

Telephone Expenses0.03

Travelling Expenses0.00

Website and Software0.45

Professional charges0.06

Total

14.07

For TRANSGENE BIOTEK LIMITEDDr.K.Koteswara RaoManaging DirectorDate: 07/08/2025Place:Hyderabad

----------------Page (11) Break----------------